CRISPR Therapeutics (CRSP) earnings per share (EPS)

Earnings per share · fiscal 2025
-$6.47

CRISPR Therapeutics (CRSP) reported diluted earnings per share of -$6.47 in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$4.34. Figures as of 17 Nov 2026, 23:34 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Earnings per share, fiscal 2025
-$6.47
Highest on record
$4.70fiscal 2021
Lowest on record
-$8.36fiscal 2022
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

CRISPR Therapeutics earnings per share (EPS), in more detail

Across the 9 fiscal years on record (2017–2025), the highest was $4.70 in fiscal 2021 and the lowest -$8.36 in fiscal 2022.

History · 9 fiscal years

Earnings per share by fiscal year

CRISPR Therapeutics earnings per share (EPS), year by year

CRISPR Therapeutics (CRSP) earnings per share (EPS) by fiscal year
Fiscal yearEarnings per shareChangeYear ended
2025-$6.47—
2024-$4.34—
2023-$1.94—
2022-$8.36 277.9% down
2021$4.70—
2020-$5.29 552.1% down
2019$1.17—
2018-$3.44—
2017-$1.71—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

How to read it

It shows how much profit stands behind each share, so it rises when profit grows or when buybacks shrink the share count.

Earnings per share at health care companies of similar size

Earnings per share of CRISPR Therapeutics and comparable companies
CompanyEarnings per shareFiscal year
MiniMed Group MMED-$1.302026
Adaptive Biotechnologies ADPT-$0.392025
Heartflow HTFL-$3.172025
CRISPR Therapeutics CRSP-$6.472025
Travere Therapeutics TVTX-$0.292025
Option Care Health OPCH$1.272025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CRSP

CRISPR Therapeutics, figure by figure

CRISPR Therapeutics (CRSP) overview: price, valuation and scorecardAll health care companies by market value

CRISPR Therapeutics earnings per share (EPS): questions and answers

What is CRISPR Therapeutics's diluted earnings per share?

CRISPR Therapeutics (CRSP) reported diluted earnings per share of -$6.47 in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$4.34.

What are the highest and lowest diluted earnings per share figures on record for CRISPR Therapeutics?

Across the 9 fiscal years on record (2017–2025), the highest was $4.70 in fiscal 2021 and the lowest -$8.36 in fiscal 2022.

How is CRISPR Therapeutics's diluted earnings per share calculated?

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “CRISPR Therapeutics (CRSP) earnings per share (EPS)”, data as of 17 November 2026. https://funkfolio.com/stock/CRSP/eps

Underlying data: the company's filings with the SEC and Yahoo Finance.